Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol by Redman, Mary W, Prof, Papadimitrakopoulou, Vassiliki A, Prof, Minichiello, Katherine, MS, Hirsch, Fred R, Prof, Mack, Philip C, PhD, Schwartz, Lawrence H, Prof, Vokes, Everett, Prof, Ramalingam, Suresh, Prof, Leighl, Natasha, MD, Bradley, Jeff, Prof, Miao, Jieling, MS, Moon, James, MS, Highleyman, Louise, BS, Miwa, Crystal, BS, LeBlanc, Michael L, Prof, Malik, Shakun, MD, Miller, Vincent A, MD, Sigal, Ellen V, PhD, Adam, Stacey, PhD, Wholley, David, MS, Sigman, Caroline, PhD, Smolich, Beverly, PhD, Blanke, Charles D, Prof, Kelly, Karen, Prof, Gandara, David R, Prof, Herbst, Roy S, Prof

Get full text

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, s... by Rizvi, Naiyer A, Dr, Mazières, Julien, Prof, Planchard, David, MD, Stinchcombe, Thomas E, MD, Dy, Grace K, MD, Antonia, Scott J, MD, Horn, Leora, MD, Lena, Hervé, MD, Minenza, Elisa, MD, Mennecier, Bertrand, MD, Otterson, Gregory A, MD, Campos, Luis T, MD, Gandara, David R, MD, Levy, Benjamin P, MD, Nair, Suresh G, MD, Zalcman, Gérard, Prof, Wolf, Jürgen, Prof, Souquet, Pierre-Jean, MD, Baldini, Editta, MD, Cappuzzo, Federico, MD, Chouaid, Christos, MD, Dowlati, Afshin, MD, Sanborn, Rachel, MD, Lopez-Chavez, Ariel, MD, Grohe, Christian, Prof, Huber, Rudolf M, Prof, Harbison, Christopher T, PhD, Baudelet, Christine, PhD, Lestini, Brian J, MD, Ramalingam, Suresh S, Prof

Get full text

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512)... by Neal, Joel W, Dr, Dahlberg, Suzanne E, PhD, Wakelee, Heather A, MD, Aisner, Seena C, Prof, Bowden, Michaela, PhD, Huang, Ying, MD, Carbone, David P, Prof, Gerstner, Gregory J, MD, Lerner, Rachel E, MD, Rubin, Jerome L, MD, Owonikoko, Taofeek K, MD, Stella, Philip J, MD, Steen, Preston D, MD, Khalid, Ahmed Ali, MD, Ramalingam, Suresh S, Prof

Get full text

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial by Ramalingam, Suresh S, Prof, Jänne, Pasi A, Prof, Mok, Tony, Prof, O'Byrne, Kenneth, Prof, Boyer, Michael J, Prof, Von Pawel, Joachim, Prof, Pluzanski, Adam, MD, Shtivelband, Mikhail, MD, Docampo, Lara Iglesias, MD, Bennouna, Jaafar, MD, Zhang, Hui, PhD, Liang, Jane Q, PhD, Doherty, Jim P, PhD, Taylor, Ian, PhD, Mather, Cecile B, MS, Goldberg, Zelanna, MD, O'Connell, Joseph, MD, Paz-Ares, Luis, Prof

Get full text

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis by Antonia, Scott J, MD, Borghaei, Hossein, DO, Ramalingam, Suresh S, MD, Horn, Leora, MD, De Castro Carpeño, Javier, MD, Pluzanski, Adam, MD, Burgio, Marco A, MD, Garassino, Marina, MD, Chow, Laura Q M, MD, Gettinger, Scott, MD, Crinò, Lucio, Prof, Planchard, David, MD, Butts, Charles, MD, Drilon, Alexander, MD, Wojcik-Tomaszewska, Joanna, MD, Otterson, Gregory A, MD, Agrawal, Shruti, PhD, Li, Ang, PhD, Penrod, John R, PhD, Brahmer, Julie, MD

Get full text